‌

US Patent 8603501 Cancer cell targeting using nanoparticles

Patent 8603501 was granted and assigned to BIND Therapeutics on December, 2013 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

BIND Therapeutics

0

Current Assignee

BIND Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Date of Patent

December 10, 2013

0

Patent Application Number

138913620

Date Filed

May 10, 2013

0

Patent Citations Received

US Patent 11951190 Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer

0

US Patent 12077501 Compounds and compositions for intracellular delivery of agents

0

US Patent 11969506 Lipid nanoparticle formulation

0

US Patent 12091693 PSMA binding ligand-linker conjugates and methods for using

0

US Patent 12090235 Preparation of lipid nanoparticles and methods of administration thereof

0

US Patent 11744801 Methods of making lipid nanoparticles

US Patent 11786607 RNA formulations

US Patent 11931430 Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer

0

Patent Primary Examiner

0

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8603501 Cancer cell targeting using nanoparticles

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool